Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
11 April 2012
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
19 March 2012
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
20 February 2012
Oryzon participates in a R&D European consortium in Parkinson’s disease
6 February 2012
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
26 January 2012
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
15 September 2011
Oryzon will launch its first product onto the market
13 September 2011
ORYZON, PALO BIOPHARMA AND AROMICS awarded with funding for JOINT research program
7 July 2011
Oryzon on the official program of the Euromediag International Convention (EIC 2011)
6 July 2011
Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine
27 June 2011
Oryzon is present at the Bio International Convention of USA
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
next ›
last »